Buy now (speculative biotech): sentiment/positioning is bullish (heavy insider + hedge fund buying; very bullish open-interest skew), while price is sitting near a key pivot that can trigger momentum.
No Intellectia edge today: AI Stock Picker and SwingMax show no active buy signal, so this is not a “high-conviction timing” entry—more of a sentiment + pipeline-driven buy.
Near-term price expectations look slightly negative per pattern stats (next month bias down), but Wall Street targets and ownership flows skew the risk/reward to the upside from ~$3.9.
Technical Analysis
Trend/ momentum: MACD histogram is positive (0.0135) and expanding → mild bullish momentum building.
RSI (6) at 51.05 → neutral; not overbought, not oversold.
Moving averages converging → compression/indecision; often precedes a larger move.
Levels: price ~3.89 is just below Pivot 3.923. A clean push/hold above ~3.92 improves odds of testing R1 4.103 then R2 4.214; downside supports are S1 3.744 then S2 3.633.
Quant pattern read-through: similar-pattern stats imply ~70% chance of slight weakness (next day -0.64%, next month -2.92%), so the setup can be choppy even if longer-term thesis is constructive.
Positioning: Open-interest put/call ratio 0.2 is strongly call-heavy → bullish longer-horizon positioning.
Flow today: volume put/call ratio 1.12 is slightly put-heavier on the day → some short-term hedging/defensiveness.
Volatility: very high (HV ~97.2; 30D IV ~113.98). IV percentile ~51 suggests elevated but not extreme vs its own history; options are pricing big moves.
Activity: today’s volume 3738 (102% of 30D avg) and open interest elevated (~113% vs avg) → engaged options market, supportive of a catalyst-style stock.
Technical Summary
Sell
7
Buy
5
Positive Catalysts
with improving MACD → potential for an upside break toward 4.10–4.21 if bid strength appears.
Neutral/Negative Catalysts
No fresh news catalysts in the last week → price may drift/mean-revert until a new event hits.
Revenue: $749K, +1772.5% YoY (likely from a low base; still small absolute level).
Profitability: Net income -$61.07M (loss), improved vs prior year per provided YoY change; still meaningfully negative.
EPS: -$0.28, improved ~75% YoY.
Gross margin: 100% (as reported), but overall financial profile remains R&D/clinical-stage with losses dominating.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent coverage is decisively bullish: two initiations with Buy ratings.
Guggenheim (2026-01-20): Buy, PT $11, citing differentiated leadership in next-gen psychiatry and strength of BPL-003 post-merger.
JonesResearch (2025-12-23): Buy, PT $16, emphasizing differentiated psychedelic/empathogenic pipeline and favorable asset characteristics (short half-lives) for treatment-resistant depression.
Wall Street pros: strong upside PTs tied to lead-asset positioning and merger synergies.
Wall Street cons: implied by stage/financials—clinical execution and commercialization timing are the key swing factors (no negative analyst actions shown, but those are the typical pressure points in this category).
Politicians/congress: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 13.13 USD with a low forecast of 10 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 13.13 USD with a low forecast of 10 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.410
Low
10
Averages
13.13
High
16
Current: 3.410
Low
10
Averages
13.13
High
16
Guggenheim
NULL -> Buy
initiated
$11
AI Analysis
2026-01-20
Reason
Guggenheim
Price Target
$11
AI Analysis
2026-01-20
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Atai Beckley with a Buy rating and $11 price target based on the company's position as "a differentiated leader in next-generation psychiatry." The recent merger with Beckley Psytech secures full ownership of the lead asset, BPL-003, which has demonstrated "compelling" Phase IIIb efficacy and durability in treatment-resistant depression, notes the analyst, who believes BPL-003 is "uniquely positioned for rapid clinical adoption and commercial scale."
JonesResearch
Justin Walsh
initiated
$16
2025-12-23
Reason
JonesResearch
Justin Walsh
Price Target
$16
2025-12-23
initiated
Reason
JonesResearch analyst Justin Walsh initiated coverage of Atai Beckley with a Buy rating and $16 price target. The firm believes the company's pipeline of psychedelic and empathogenic drugs offer "differentiated opportunities" in large neuropsychiatric indications. Atai Beckley will benefit from current trends favoring the development of drugs in these classes, the analyst tells investors in a research note. Jones thinks the short half-lives of Atai's lead assets BPL-003 and VLS-01 will allow their use in treatment resistant depression.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATAI
